LEAP FORWARD 2021 #1: Innovate Faster

The FACC-NY is excited to unveil a brand new brand and energy between the group of 20 bi-national chambers: LEAP Atlantic

For decades, bi-national member chambers have worked together to produce world-class events in New York City, including the annual Central Park Boathouse European Spring Networking Event, various European Start-up Pitch Nights and other multi-Chamber events. These gatherings are known for their high-quality audience, content and atmosphere.  The 2021 European-American Business Trends Series will be no exception! 

Participating Chambers include the French-American Chamber of Commerce, the German-American Chamber of Commerce, BelCham, Spain-U.S. Chamber of Commerce and Italy-American Chamber of Commerce. Collectively, the 20 participating Bi-National European Chambers of Commerce – LEAP ATLANTIC -  reach over 4,000 member companies and tens of thousands of European and American business leaders across the New York area, as well as around the world.

Session-Specific speakers to be announced soon!

Interested in sponsorship opportunities? Contact Katelyn Heath at kheath@faccnyc.org.

➤ April 22, 2021: #1 INNOVATE FASTER

Innovation in the digital realm has been a leading driver of European and American economies while transatlantic technology investment is giving rise to not only start-ups, but to global market leaders. In this panel, we will identify how successful transatlantic ventures are achieving success and hear from experts on opportunities for additional cross-border investment.

➤ May 6, 2021: #2 (RE)BUILD SMARTER

While the world’s demand for energy and clean water continue to grow alongside greenhouse gases, companies throughout Europe and the United States are devising innovative solutions to address these global concerns.  With the United States back among Paris accord signatories, the transatlantic relationship will be key force to developing and implementing financially viable sustainability models.

➤ May 27, 2021: #3 LIVE HEALTHIER

Biotechnology, gene therapy and the use of artificial intelligence are changing the face of healthcare, with European and American firms at the forefront of research, development, and commercialization.  Start-up ventures now compete around the world with entrenched players to develop the next lifesaving treatment.  Policy and ethical issues are stirring considerable debate in European-American life sciences circles, while many are seeing investment opportunities that attract global capital.